Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib after NECS in vitiligo
NCT06454461Recruiting
- Sponsor
- Jilin University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of upadacitinib in Vitiligo (2 arms), sponsored by Jilin University. Primary endpoint: Total Vitiligo Area Scoring Index at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06454461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454461.